Salvatore Siena, MD, explains the mechanism of action of trastuzumab deruxtecan and its promise

Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patientsПодробнее

Dr. O’Regan on the Mechanism of Action of TrastuzumabПодробнее

Herceptin (trastuzumab) for HER2-Positive Breast and Stomach CancerПодробнее

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancerПодробнее

Herceptin: Mechanism of actionПодробнее

Trastuzumab Deruxtecan for Breast Cancer | NEJMПодробнее

Breast Cancer Drug - Trastuzumab Emtansine - Mechanism of ActionПодробнее

Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical developmentПодробнее

Two Dimensions in Targeting HER2Подробнее

Breast Cancer Chess Championship: Trastuzumab vs HER2 ReceptorПодробнее

Breast Reconstruction - Body & Soul: Eran Bar-Meir at TEDxJaffa 2013Подробнее

What is a TAVR? - Summa HealthПодробнее

The evolution of HER2 targeting in metastatic breast breast cancerПодробнее

Study of DS-8201a in HER2-Low, Unresectable and/or Metastatic Breast CancerПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

METASTATIC BREAST CANCER: ENHERTU STOPS THE SPREADПодробнее

Dr. Hamilton Discusses Trastuzumab deruxtecan - NBCLXПодробнее

HER2-low expression in breast cancerПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее